All In Biotech

Drug Trial Radar · NCT07537075

An Extension of SKY-0515 in Participants With Huntington's Disease

An Open Label Extension of SKY-0515 in Participants With Huntington's Disease Who Completed a Prior SKY-0515 Treatment Study

Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

500

Planned (sponsor's estimate)

Start

Apr 10, 2026

Primary completion

Dec 2029

Study completion Dec 2029

Sponsor

Lead sponsor
Skyhawk Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to test if the drug SKY-0515, an oral medication, can lower harmful proteins linked to Huntington's Disease (HD) and improve the symptoms of participants with HD. This study includes men and women aged 25 and older who have HD confirmed by genetic testing and meet certain requirements for physical ability and independence.

Conditions

  • Huntington's Disease (HD)

Interventions

  • SKY-0515Drug

    Study Drug Name (INN): SKY-0515 Type: Drug (small molecule) Dosage Level(s): 9mg Route of Administration: Oral Dosage Frequency: Once daily Treatment Duration: until drug becomes commercially available or until the development of SKY-0515 is terminated by the Sponsor. Use: Experimental Sourcing: SKY-0515 will be provided centrally by the Sponsor or subsidiary, or designee Packaging and Labeling: Study drug will be provided in bottles labeled as required per country requirement. All packaging and labeling operations for the study drug will be performed according to current Good Manufacturing Practice for Medicinal Products and the relevant regulatory requirements.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Long-term safety and tolerability of SKY-0515Time frame: Continuously from enrollment to study completion or approximately 36 months

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • John Hunter Hospital

    New Lambton Heights, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • The University of Queensland

    Herston, Queensland, Australia

  • Flinders Medical Centre

    Adelaide, South Australia, Australia

  • Calvary Health Care Bethlehem

    Caulfield South, Victoria, Australia

  • The Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • The Perron Institute for Neurology and Translational Science (Perron Institute)

    Nedlands, Western Australia, Australia

  • Huntington's Disease Association

    Auckland, New Zealand

  • New Zealand Brain and Research Institute

    Christchurch, New Zealand

  • Wellington Hospital

    Wellington, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.